CN101305011B - 吡啶衍生物及其在治疗精神障碍中的用途 - Google Patents
吡啶衍生物及其在治疗精神障碍中的用途 Download PDFInfo
- Publication number
- CN101305011B CN101305011B CN2006800418603A CN200680041860A CN101305011B CN 101305011 B CN101305011 B CN 101305011B CN 2006800418603 A CN2006800418603 A CN 2006800418603A CN 200680041860 A CN200680041860 A CN 200680041860A CN 101305011 B CN101305011 B CN 101305011B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- compound
- solution
- mmol
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 COC(C[C@]1NCCC1)=*C* Chemical compound COC(C[C@]1NCCC1)=*C* 0.000 description 7
- PXYNCQRQUOOTSQ-QMMMGPOBSA-N C(C1)CN2[C@@H]1CCNCC2 Chemical compound C(C1)CN2[C@@H]1CCNCC2 PXYNCQRQUOOTSQ-QMMMGPOBSA-N 0.000 description 1
- DAZREHXORNHICT-UHFFFAOYSA-N CC(C(C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1)O)c(c(-c(cc1)c(C)cc1F)c1)cnc1N(CCN1C2COCC1)C2=O Chemical compound CC(C(C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1)O)c(c(-c(cc1)c(C)cc1F)c1)cnc1N(CCN1C2COCC1)C2=O DAZREHXORNHICT-UHFFFAOYSA-N 0.000 description 1
- WGIGVTCGIGERNO-AVJYQCBHSA-O CC(C)(C(N(C)c(c(-c(cc1)c(C)cc1F)c1)cnc1N(C1)[C@@H](COC)CN(CC2)C1C[SH+]2(O)OC)=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 Chemical compound CC(C)(C(N(C)c(c(-c(cc1)c(C)cc1F)c1)cnc1N(C1)[C@@H](COC)CN(CC2)C1C[SH+]2(O)OC)=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 WGIGVTCGIGERNO-AVJYQCBHSA-O 0.000 description 1
- XDAVSKQFRCAXOY-SANMLTNESA-N CC(C)(C(N(C)c(c(-c(cc1)c(C)cc1F)c1)cnc1N(CCCN1[C@H]2CCC1)C2=O)=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 Chemical compound CC(C)(C(N(C)c(c(-c(cc1)c(C)cc1F)c1)cnc1N(CCCN1[C@H]2CCC1)C2=O)=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 XDAVSKQFRCAXOY-SANMLTNESA-N 0.000 description 1
- UMEVTBXNROQUQZ-UHFFFAOYSA-N CC(C)(C(N(C)c(c(-c(cc1)c(C)cc1F)c1)cnc1N1CC(C(NCC2)=O)N2CC1)=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 Chemical compound CC(C)(C(N(C)c(c(-c(cc1)c(C)cc1F)c1)cnc1N1CC(C(NCC2)=O)N2CC1)=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 UMEVTBXNROQUQZ-UHFFFAOYSA-N 0.000 description 1
- UXCBTZDZHHGJKO-UHFFFAOYSA-N CC(C)(C(N(C)c(c(-c(cc1)c(C)cc1F)c1)cnc1N1CC(CO)N(CCC2)C2C1)=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 Chemical compound CC(C)(C(N(C)c(c(-c(cc1)c(C)cc1F)c1)cnc1N1CC(CO)N(CCC2)C2C1)=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 UXCBTZDZHHGJKO-UHFFFAOYSA-N 0.000 description 1
- YFMZALAUALIBHT-UHFFFAOYSA-N CC(C)(C(N(C)c(c(-c1c(C)cccc1)c1)cnc1N(CC1)CC2N1CCOC2)=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 Chemical compound CC(C)(C(N(C)c(c(-c1c(C)cccc1)c1)cnc1N(CC1)CC2N1CCOC2)=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 YFMZALAUALIBHT-UHFFFAOYSA-N 0.000 description 1
- FJFVREVNXQAOGZ-PZORYLMUSA-N CC(C)(C)OC(N(CC1)CC(C(N[C@H](CO)C(OC)=O)=O)N1C(OC(C)(C)C)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CC(C(N[C@H](CO)C(OC)=O)=O)N1C(OC(C)(C)C)=O)=O FJFVREVNXQAOGZ-PZORYLMUSA-N 0.000 description 1
- IIZGWFQKLVCLLA-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CC(C(O)=O)N1C(OC(C)(C)C)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CC(C(O)=O)N1C(OC(C)(C)C)=O)=O IIZGWFQKLVCLLA-UHFFFAOYSA-N 0.000 description 1
- PXRKWLBROJKTLG-YHMJZVADSA-N CC(C)(C)OC(N(CCOC1)C1C(N[C@H](CO)C(OC)=O)=O)=O Chemical compound CC(C)(C)OC(N(CCOC1)C1C(N[C@H](CO)C(OC)=O)=O)=O PXRKWLBROJKTLG-YHMJZVADSA-N 0.000 description 1
- KVXXEKIGMOEPSA-UHFFFAOYSA-N CC(C)(C)OC(N(CCOC1)C1C(O)=O)=O Chemical compound CC(C)(C)OC(N(CCOC1)C1C(O)=O)=O KVXXEKIGMOEPSA-UHFFFAOYSA-N 0.000 description 1
- CTDIKDIZNAGMFK-UHFFFAOYSA-N CC(C)(C)OC(N(CCSC1)C1C(O)=O)=O Chemical compound CC(C)(C)OC(N(CCSC1)C1C(O)=O)=O CTDIKDIZNAGMFK-UHFFFAOYSA-N 0.000 description 1
- MCFFCQNSBLVXKS-OAHLLOKOSA-N CC(C)(C)OC(N1[C@@H](CNC(OCc2ccccc2)=O)CCC1)=O Chemical compound CC(C)(C)OC(N1[C@@H](CNC(OCc2ccccc2)=O)CCC1)=O MCFFCQNSBLVXKS-OAHLLOKOSA-N 0.000 description 1
- NFRFKIUDOXVXNV-GFCCVEGCSA-N CCOC([C@@H](COC1)N(Cc2ccccc2)C1=O)=O Chemical compound CCOC([C@@H](COC1)N(Cc2ccccc2)C1=O)=O NFRFKIUDOXVXNV-GFCCVEGCSA-N 0.000 description 1
- DOPPZLDDCUSBAF-OEMAIJDKSA-N CCOC([C@H]1COCCCC(Cc2ccccc2)C1)=O Chemical compound CCOC([C@H]1COCCCC(Cc2ccccc2)C1)=O DOPPZLDDCUSBAF-OEMAIJDKSA-N 0.000 description 1
- YIFCZNGSHKDPMH-UHFFFAOYSA-N CN(CCSC1)C1C(NC(CO)C(OC)=O)=O Chemical compound CN(CCSC1)C1C(NC(CO)C(OC)=O)=O YIFCZNGSHKDPMH-UHFFFAOYSA-N 0.000 description 1
- ANSUDRATXSJBLY-GSVOUGTGSA-N COC([C@@H](CO)N)=O Chemical compound COC([C@@H](CO)N)=O ANSUDRATXSJBLY-GSVOUGTGSA-N 0.000 description 1
- LTQSJQPTKFNKTH-UHFFFAOYSA-N FCC(CN(CCC1)C1C1)N1P Chemical compound FCC(CN(CCC1)C1C1)N1P LTQSJQPTKFNKTH-UHFFFAOYSA-N 0.000 description 1
- YEJJVVXWENVTAU-UHFFFAOYSA-N FCC1NCC(CCC2)N2C1 Chemical compound FCC1NCC(CCC2)N2C1 YEJJVVXWENVTAU-UHFFFAOYSA-N 0.000 description 1
- DPVSPOJGBBOZGB-UHFFFAOYSA-N O=C(CN1)N(CCNC2)C2C1=O Chemical compound O=C(CN1)N(CCNC2)C2C1=O DPVSPOJGBBOZGB-UHFFFAOYSA-N 0.000 description 1
- QXKAIPFKHPAPLY-ZETCQYMHSA-N O=C1NCCN(CCC2)[C@@H]2C1 Chemical compound O=C1NCCN(CCC2)[C@@H]2C1 QXKAIPFKHPAPLY-ZETCQYMHSA-N 0.000 description 1
- JNTSDSBEAXSUAU-LWOQYNTDSA-N OC[C@H](C(N1C2COCC1)=O)NC2=O Chemical compound OC[C@H](C(N1C2COCC1)=O)NC2=O JNTSDSBEAXSUAU-LWOQYNTDSA-N 0.000 description 1
- OPEBSOKNWMAPLB-JAMMHHFISA-N OC[C@H]1NCC(COCC2)N2C1 Chemical compound OC[C@H]1NCC(COCC2)N2C1 OPEBSOKNWMAPLB-JAMMHHFISA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0518472A GB0518472D0 (en) | 2005-09-09 | 2005-09-09 | Novel compounds |
| GB0518472.6 | 2005-09-09 | ||
| GB0611153A GB0611153D0 (en) | 2006-06-06 | 2006-06-06 | Novel compounds |
| GB0611153.8 | 2006-06-06 | ||
| PCT/EP2006/008845 WO2007028654A1 (en) | 2005-09-09 | 2006-09-07 | Pyridine derivatives and their use in the treatment of psychotic disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101305011A CN101305011A (zh) | 2008-11-12 |
| CN101305011B true CN101305011B (zh) | 2011-03-02 |
Family
ID=37546936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006800418603A Active CN101305011B (zh) | 2005-09-09 | 2006-09-07 | 吡啶衍生物及其在治疗精神障碍中的用途 |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US7683056B2 (enExample) |
| EP (2) | EP2336136A1 (enExample) |
| JP (1) | JP5121716B2 (enExample) |
| KR (1) | KR101292348B1 (enExample) |
| CN (1) | CN101305011B (enExample) |
| AR (1) | AR058805A1 (enExample) |
| AT (1) | ATE505472T1 (enExample) |
| AU (1) | AU2006289281B2 (enExample) |
| BR (1) | BRPI0615787B8 (enExample) |
| CA (1) | CA2621564C (enExample) |
| CR (1) | CR9847A (enExample) |
| CY (1) | CY1111907T1 (enExample) |
| DE (1) | DE602006021323D1 (enExample) |
| DK (1) | DK1928886T3 (enExample) |
| EA (1) | EA013909B1 (enExample) |
| HR (1) | HRP20110457T1 (enExample) |
| IL (1) | IL189578A (enExample) |
| JO (1) | JO2722B1 (enExample) |
| MA (1) | MA29780B1 (enExample) |
| MY (1) | MY145713A (enExample) |
| NO (1) | NO340921B1 (enExample) |
| NZ (1) | NZ565983A (enExample) |
| PE (1) | PE20070614A1 (enExample) |
| PL (1) | PL1928886T3 (enExample) |
| PT (1) | PT1928886E (enExample) |
| SI (1) | SI1928886T1 (enExample) |
| TW (1) | TWI378101B (enExample) |
| WO (1) | WO2007028654A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007039123A2 (en) * | 2005-09-22 | 2007-04-12 | Smithkline Beecham Corporation | Combination therapy comprising an nk-3 antagonist and an antipsychotic agent |
| TW200730494A (en) * | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| EP1943216B1 (en) * | 2005-10-10 | 2010-06-30 | Glaxo Group Limited | Prolinamide derivatives as sodium channel modulators |
| DK2774925T3 (en) | 2005-11-08 | 2017-02-27 | Vertex Pharma | Heterocyclic modulators of ATP binding cassette transporters |
| US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| WO2008090114A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
| KR20100007956A (ko) | 2007-05-03 | 2010-01-22 | 화이자 리미티드 | 나트륨 채널 조절제로서의 2-피리딘 카복스아마이드 유도체 |
| NZ581259A (en) | 2007-05-09 | 2012-07-27 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| AU2008335440B2 (en) | 2007-12-07 | 2013-11-07 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| CN103626744B (zh) | 2007-12-07 | 2016-05-11 | 沃泰克斯药物股份有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的固体形式 |
| EP2098526B1 (en) * | 2008-02-22 | 2014-01-15 | Neurotune AG | Nitrogen-containing bicyclic compounds active on chronic pain conditions |
| JP5523352B2 (ja) | 2008-02-28 | 2014-06-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｃｆｔｒ修飾因子としてのへテロアリール誘導体 |
| FR2928150A1 (fr) | 2008-02-29 | 2009-09-04 | Vetoquinol Sa Sa | Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens |
| WO2009119528A1 (ja) * | 2008-03-24 | 2009-10-01 | 武田薬品工業株式会社 | 複素環化合物 |
| GB0808747D0 (en) * | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
| EP2145891A1 (en) | 2008-07-09 | 2010-01-20 | Vetoquinol S.A. | 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials |
| GB0814340D0 (en) * | 2008-08-05 | 2008-09-10 | Smithkline Beecham Corp | Anhydrous crystol form fo a pyridine derivative |
| US20110034469A1 (en) | 2009-08-04 | 2011-02-10 | Takeda Pharmaceutical Company Limited | Heterocyclic Compound |
| IN2012DN01292A (enExample) * | 2009-08-27 | 2015-06-05 | Glaxosmithkline Llc | |
| WO2011054773A1 (en) | 2009-11-03 | 2011-05-12 | Glaxosmithkline Llc | Novel lactam compounds |
| EP2555755B2 (en) | 2010-04-07 | 2019-07-10 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof |
| EP2590953B1 (en) | 2010-07-09 | 2014-10-29 | Convergence Pharmaceuticals Limited | Tetrazole compounds as calcium channel blockers |
| US8648118B2 (en) | 2010-12-17 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Bicyclic ring system substituted amide functionalised phenols as medicaments |
| CN102617503B (zh) * | 2011-03-03 | 2014-05-07 | 上海常丰生物医药科技有限公司 | (s)-3-吗啉基羧酸的合成方法 |
| WO2013049164A1 (en) * | 2011-09-29 | 2013-04-04 | Abbvie Inc. | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS |
| WO2013049174A1 (en) | 2011-09-29 | 2013-04-04 | Abbvie Inc. | Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers |
| CN105008361A (zh) | 2012-12-12 | 2015-10-28 | 艾伯维公司 | 作为钙通道阻滞剂用于治疗疼痛的的二氮杂*衍生物 |
| RU2673084C2 (ru) | 2013-11-08 | 2018-11-22 | Киссеи Фармасьютикал Ко., Лтд. | Производное карбоксиметилпиперидина |
| HRP20210516T2 (hr) | 2013-11-12 | 2021-10-01 | Vertex Pharmaceuticals Incorporated | Postupak proizvodnje farmaceutskih pripravaka za liječenje bolesti koje su posredovane putem cftr |
| TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
| WO2016021562A1 (ja) * | 2014-08-06 | 2016-02-11 | キッセイ薬品工業株式会社 | シアノチオフェン誘導体 |
| DK3221692T3 (da) | 2014-11-18 | 2021-08-23 | Vertex Pharma | Fremgangsmåde til udførsel af tests med høj kapacitet ved hjælp af højtryksvæskekromatografi |
| ES2912881T3 (es) | 2014-12-23 | 2022-05-30 | Convergence Pharmaceuticals | Procedimiento para preparar derivados de alfa-carboxamida pirrolidina |
| WO2016184829A1 (en) * | 2015-05-18 | 2016-11-24 | Nerre Therapeutics Limited | Dual nk-1/nk-3 receptor antagonists for the treatment of sex-hormone-dependent diseases |
| CA3076823A1 (en) | 2017-10-05 | 2019-04-11 | Biogen Inc. | Process for preparing alpha-carboxamide pyrrolidine derivatives |
| EA202092131A1 (ru) | 2018-03-14 | 2020-11-27 | Кэнди Терапьютикс Лимитед | Новый фармацевтический препарат, содержащий двойные антагонисты рецептора nk-1/nk-3 |
| US11583538B2 (en) | 2019-04-08 | 2023-02-21 | Venenum Biodesign, LLC | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors |
| PE20221167A1 (es) * | 2019-11-15 | 2022-07-25 | Kandy Therapeutics Ltd | Nuevo proceso quimico para la elaboracion de 6-cloro-4-(4-fluoro-2-metilfenil)piridin-3-amina, un intermediario clave de nt-814 |
| WO2021261969A1 (ko) * | 2020-06-26 | 2021-12-30 | 홀로스메딕 주식회사 | 신규한 화합물의 제조방법 |
| KR102682775B1 (ko) * | 2020-06-26 | 2024-07-08 | 홀로스메딕 주식회사 | 신규한 화합물의 제조방법 |
| WO2022075974A1 (en) * | 2020-10-06 | 2022-04-14 | Venenum Biodesign, LLC | Cyclic trex1 inhibitors |
| CN117425472A (zh) * | 2021-04-05 | 2024-01-19 | 小利兰·斯坦福大学托管委员会 | 对神经传递的对映体选择性作用 |
| EP4431512A1 (en) | 2023-03-16 | 2024-09-18 | Bayer Consumer Care AG | Novel dual nk-1/nk-3 receptor antagonists |
| WO2025242584A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | A stable soft gelatin capsule formulation for elinzanetant |
| WO2025242585A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant |
| WO2025242583A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | Novel formulation comprising elinzanetant in a solid dispersion |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005002577A1 (en) * | 2003-07-03 | 2005-01-13 | F. Hoffmann-La Roche Ag | Dual nk1/nk3 antagonists for treating schizophrenia |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4921855A (en) | 1987-06-22 | 1990-05-01 | Fujisawa Pharmaceutical Co., Ltd. | New Histidyl amino acid derivatives, and pharmaceutical composition comprising the same |
| US5166203A (en) | 1990-08-30 | 1992-11-24 | Kanebo, Ltd. | Quinolinecarboxylic acid derivatives, antibacterial agent containing the same |
| SI1004583T1 (en) | 1998-11-23 | 2004-12-31 | Pfizer Products Inc. | Process and hydantoin intermediates for the synthesis of growth hormone secretagogues |
| ES2226622T3 (es) | 1999-02-24 | 2005-04-01 | F. Hoffmann-La Roche Ag | Derivados de 4-fenil piridina y su empleo como antagonistas del receptor nk-1. |
| DOP2000000107A (es) | 1999-12-01 | 2002-09-16 | Agouron Pharmaceutical Inc | Compuestos, composiciones y metodos para estimular el crecimiento y alongamiento de las neuronas |
| TWI259180B (en) | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
| GB0203020D0 (en) | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| GB0203022D0 (en) | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| TW200407324A (en) | 2002-05-17 | 2004-05-16 | Bristol Myers Squibb Co | Bicyclic modulators of androgen receptor function |
-
2006
- 2006-09-07 US US12/065,923 patent/US7683056B2/en active Active
- 2006-09-07 EP EP10190918A patent/EP2336136A1/en not_active Withdrawn
- 2006-09-07 EP EP06777183A patent/EP1928886B1/en active Active
- 2006-09-07 AT AT06777183T patent/ATE505472T1/de active
- 2006-09-07 JP JP2008529564A patent/JP5121716B2/ja active Active
- 2006-09-07 BR BRPI0615787A patent/BRPI0615787B8/pt active IP Right Grant
- 2006-09-07 NZ NZ565983A patent/NZ565983A/en not_active IP Right Cessation
- 2006-09-07 EA EA200800784A patent/EA013909B1/ru unknown
- 2006-09-07 DE DE602006021323T patent/DE602006021323D1/de active Active
- 2006-09-07 CN CN2006800418603A patent/CN101305011B/zh active Active
- 2006-09-07 PL PL06777183T patent/PL1928886T3/pl unknown
- 2006-09-07 MY MYPI20064110A patent/MY145713A/en unknown
- 2006-09-07 PE PE2006001077A patent/PE20070614A1/es not_active Application Discontinuation
- 2006-09-07 JO JO2006301A patent/JO2722B1/en active
- 2006-09-07 CA CA2621564A patent/CA2621564C/en active Active
- 2006-09-07 AR ARP060103894A patent/AR058805A1/es active IP Right Grant
- 2006-09-07 DK DK06777183.2T patent/DK1928886T3/da active
- 2006-09-07 PT PT06777183T patent/PT1928886E/pt unknown
- 2006-09-07 HR HR20110457T patent/HRP20110457T1/hr unknown
- 2006-09-07 KR KR1020087008441A patent/KR101292348B1/ko active Active
- 2006-09-07 SI SI200631047T patent/SI1928886T1/sl unknown
- 2006-09-07 WO PCT/EP2006/008845 patent/WO2007028654A1/en not_active Ceased
- 2006-09-07 AU AU2006289281A patent/AU2006289281B2/en active Active
- 2006-09-07 TW TW095132989A patent/TWI378101B/zh active
-
2008
- 2008-02-18 IL IL189578A patent/IL189578A/en active IP Right Grant
- 2008-03-17 MA MA30749A patent/MA29780B1/fr unknown
- 2008-03-28 CR CR9847A patent/CR9847A/es not_active Application Discontinuation
- 2008-04-07 NO NO20081728A patent/NO340921B1/no unknown
-
2009
- 2009-12-14 US US12/636,849 patent/US7919491B2/en active Active
-
2011
- 2011-02-23 US US13/032,740 patent/US8097618B2/en active Active
- 2011-07-04 CY CY20111100641T patent/CY1111907T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005002577A1 (en) * | 2003-07-03 | 2005-01-13 | F. Hoffmann-La Roche Ag | Dual nk1/nk3 antagonists for treating schizophrenia |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101305011B (zh) | 吡啶衍生物及其在治疗精神障碍中的用途 | |
| TWI811353B (zh) | 作為parp7抑制劑的嗒酮 | |
| JP2009507801A5 (enExample) | ||
| CN107207514B (zh) | 稠环杂芳基化合物及其作为trk抑制剂的用途 | |
| TWI794232B (zh) | 激酶抑制劑及其用途 | |
| KR20230019855A (ko) | Kras g12c 단백질의 억제제 및 그의 용도 | |
| TW201605859A (zh) | 作為酪蛋白激酶１δ／ε抑制劑之新穎經取代之吡唑并－哌 | |
| CN110691784A (zh) | 抑制mcl-1蛋白的化合物 | |
| CN103313988A (zh) | 咪唑并三嗪酮化合物 | |
| WO2024083256A1 (zh) | pan-KRAS降解剂及其制备方法和应用 | |
| CN111433207B (zh) | 作为αV整合素抑制剂的吡咯并吡嗪衍生物 | |
| KR102281284B1 (ko) | 피페라진 유도체 및 약제로서의 이의 용도 | |
| CN118201915A (zh) | 作为alk5抑制剂的哒嗪基氨基衍生物 | |
| TW201602116A (zh) | 作為β－分泌酶抑制劑之橋接二環胺基噻嗪二氧化物化合物及其使用方法 | |
| CN111201226A (zh) | 环状被取代的咪唑并[4,5-c]喹啉衍生物 | |
| CN115151551B (zh) | 作为mcl-1抑制剂的大环吲哚衍生物 | |
| TWI902994B (zh) | Ｉｒａｋ４抑制劑、藥物組成物及其用途 | |
| CN117295749A (zh) | 作为mcl-1抑制剂的大环2-烯丙基四氢呋喃 | |
| HK1242314B (zh) | 稠环杂芳基化合物及其作为trk抑制剂的用途 | |
| HK1242314A1 (en) | Fused ring heteroaryl compounds and their use as trk inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: NIL MEDICAL CO., LTD. Free format text: FORMER OWNER: SMITHKLINE BEECHAM CORP. Effective date: 20130702 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C56 | Change in the name or address of the patentee |
Owner name: SMITHKLINE BEECHAM CORP. Free format text: FORMER NAME: SMITHKLINE BEECHAN CORP. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: American Pennsylvania Patentee after: GLAXOSMITHKLINE LLC Address before: American Pennsylvania Patentee before: SMITHKLINE BEECHAM Corp. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130702 Address after: Steve Niki Patentee after: NERRE THERAPEUTICS LTD. Address before: American Pennsylvania Patentee before: GLAXOSMITHKLINE LLC |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20210222 Address after: Hakuhoku County, England Patentee after: Kandi Medical Co.,Ltd. Address before: Steve Niki Patentee before: NeRRe Therapeutics Ltd. |
|
| TR01 | Transfer of patent right |